ABOUT INVETECH
Invetech helps cell and gene therapy developers to visualize, strategize and manage the future. With proven processes, expert insights and full-spectrum services, we swiftly accelerate life-changing therapies from clinical to commercial-scale manufacturing. With configurable technology platforms and automated production systems, we enable predictable, reproducible products of the highest quality and efficacy. Our integrated approach brings together biological scientists, engineers, designers and program managers to deliver successful market offerings to more people globally. Working in close collaboration with early-stage and mature life science companies, we are committed to advancing the next generation of vital, emerging therapies to revolutionize healthcare and precision medicine.
One of the continued challenges for scalable commercial manufacturing of cell therapies is closing and automating the entire manufacturing process. Many core manufacturing processes may be closed, but peripheral systems e.g. media formulation, viral vector packaging remain open – introducing opportunities for failures.
Invetech’s approach enables manufacturers to close and integrate both core and peripheral processes.
Our in-depth understanding of platforms and processes support seamless configuration and integration of equipment with single-use systems tailored for specific manufacturing needs. This complete life-cycle approach assures compatibility and quality at every stage – giving you more certainty in the outcome. All elements are robust, GMP compliant, closed, cleanable and validatable.
Our novel systems include:
- Formulation and fill of bulk media preparations and viral vectors
- Formulation and filling of cell products
- Preparation of blood products/starting materials for applications such as leukaphoresis
- Washing and harvesting cell suspensions
All these systems have been qualified and deployed in GMP manufacturing environments.
FEATURED PRODUCTS
Our cell biologists and engineers work together to assure your therapy remains unchanged by the clinical and commercial manufacturing processes. Our integrated laboratory services and applications support this effort.
Since 2003, we have helped more than 50 cell and advanced therapy companies across the globe translate their unit process steps into GMP controlled manufacturing processes on automated equipment in disposables. We understand the market and have a proven process for designing and implementing a viable plan that will allow you to seamlessly transition your cell-based therapy to commercial-scale manufacturing.
Low volume automated bag filling platform
Invetech’s award-winning automated bag filling platform can be configured to accurately dispense therapeutic products or processing material from formulated bulk into individual bag units. Utilizing aseptic single-use sets to provide sterile processing without a barrier isolator, the system provides fully automated, closed, efficient and flexible bag filling in class C or D cleanroom settings. Designed for GMP manufacturing, this configurable system is scalable and minimizes process variability.
Formulate and Fill Media with this GMP Automated Media Production Platform
Automated, closed cell and gene therapy manufacturing.
Through our Strategic Program Management approach, we plan and structure our programs to align with your objectives. All of our processes are built around identifying and mitigating risks while allowing flexibility to change and adapt our approach to deliver the best program outcome.
Products succeed when people succeed. Therefore, creating a great experience is essential to commercial success. Through observation and hands-on user testing of prototypes using methods grounded in behavioral science, we’re able to design simple, intuitive workflows, while mitigating the risk of errors. This human-centered approach is tightly integrated into our design and development processes to ensure we’re delivering engaging, easy to use products.
CONTACT INFORMATION
Invetech
9980 Huennekens Street, Suite 140
San Diego, CA 92121
UNITED STATES
Phone: (858) 437-1061
Contact: Marisa Reinoso
FEATURED ARTICLES
- 5 Things To Look Out For In Cell Therapy Supply Chain In 2022
- Guide To Transitioning Clinical Cell Therapy Manufacturing To Commercial Scale
- Selecting Cell And Gene Therapy Manufacturing Processes To Automate
- Building A Robust Cell And Gene Therapy Supply Chain
- Release By Exception Saves Time And Money In QC Activities
- How To Develop A Cell Therapy Manufacturing Roadmap
- Integrating Ancillary Systems – A Bridge To Closed Cell Therapy Manufacturing Processes
- Maximizing ROI In Cell Therapy Production
- Manufacturing And cGMP For Cell And Gene Therapies
- Closed Manufacturing System For Autologous Cell Therapy Production
- Planning Manufacturing Systems That Grow With Your Cell And Gene Therapies
- Ensuring Bioprocess Flexibility For Cell Therapy Production
- Navigating The Cost And Time Of Cell Therapy Manufacturing Process Automation
- Got Approval… Now What? Meeting Cell Therapy Market Demand
- Commercializing Disruptive Technologies In Advanced Therapies
- Manufacturing Automation Solutions For Allogeneic Cell Therapy Production
- Avoiding The Potholes Along The Pathway To Commercial Cell Therapies
BROCHURES
VIDEOS
-
![Invetech]( "Implementing Disruptive Technologies With Confidence in Cell Therapy")
Panelists from Lonza, Takeda and Vor Biopharma share their insights on how to best introduce disruptive technologies into cell therapy manufacturing processes.
-
![Invetech]( "Automating Ancillary Processes: Closing The New Bottleneck In Cell and Gene Therapy Manufacturing")
In this webinar, industry experts share common and uncommon challenges encountered when closing and automating ancillary processes, and how improved scalability and reproducibility were achieved by moving to closed automated platforms.
-
![Invetech]( "Closing Ancillary Processes: The New Bottleneck In Cell and Gene Therapy")
One of the continued challenges for scalable commercial manufacturing of cell therapies is closing and automating the entire manufacturing process. Many core manufacturing processes may be closed, but peripheral systems e.g. media formulation, viral vector packaging remain open – introducing opportunities for failures. Invetech’s approach enables manufacturers to close and integrate both core and peripheral processes.
-
![21_01_CG_InnovationCellManufaturing_1920x1080]( "Can Innovation Drive Down Cell Therapy Manufacturing Costs?")
The high cost of producing new cell and gene therapies is one of the largest issues facing the industry. After launching Kymriah and Yescarta, Novartis’ price tags were $475,000 and $375,000, respectively. Advancements in manufacturing are driving costs down, but not at the required pace.
-
![Invetech 4]( "3rd Generation Filling System Video")
3rd Generation Filling System is an automated bag filling platform for GMP manufacturing.
-
![Invetech 2]( "Cell And Gene Therapy Formulation And Fill Platform")
Solving commercial manufacturing challenges in cell and gene therapy.
-
![3rd Generation Filling system.jpg]( "Invetech 3rd Generation Filling System")
Invetech's 3rd generation filling system is an automated bag filling platform for GMP manufacturing. Watch this video to see a glimpse of the core capabilities of this system.
-
![Invetech]( "Avoiding The Potholes Along The Pathway To Commercial Cell Therapies Panel Video")
A recent panel discussion hosted by Invetech during the recent International Society Cell & Gene Therapy (ISCT) conference in Melbourne, Australia explores the main challenges along the pathway from process development to commercial cell therapies.
-
![Invetech]( "Meeting Cell Therapy Market Demand")
The commercial success of a cell-based therapeutic depends on a scalable, automated manufacturing process. But how can companies ensure their manufacturing processes are up to meeting the needs and market demand of the rapidly evolving cell therapy field? Our annual breakfast briefing at the Phacilitate Leaders World conference 2020 in Miami tackled this and other current topics.
